TOURMALINE BIO INC. - COMMON STOCK

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

27 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

10 يناير 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

10 ديسمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

14 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

07 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

31 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

15 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

11 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

08 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

03 سبتمبر 2024 07:45:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

08 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

02 أغسطس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

27 يونيو 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

23 مايو 2024 07:10:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

16 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

13 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

19 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

27 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

29 يناير 2024 16:01:00 بحسب Nasdaq GlobeNewswire